Back to Search
Start Over
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis
- Source :
- Therapeutic Advances in Medical Oncology, Vol 13 (2021)
- Publication Year :
- 2021
- Publisher :
- SAGE Publishing, 2021.
-
Abstract
- Background: The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) versus ASC alone in aESCC. Methods: We conducted a tri-center retrospective cohort study ( n = 166) including patients with aESCC who had experienced disease progression on palliative first-line therapy. A propensity score model using inverse probability of treatment weighting (IPTW) was implemented for comparative efficacy analysis of overall survival (OS) in patients with second-line + ASC ( n = 92, 55%) versus ASC alone ( n = 74, 45%). Results: The most frequent second-line regimens used were docetaxel (36%) and paclitaxel (18%). In unadjusted primary endpoint analysis, second-line + ASC was associated with significantly longer OS compared with ASC alone [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.35–0.69, p
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 17588359
- Volume :
- 13
- Database :
- Directory of Open Access Journals
- Journal :
- Therapeutic Advances in Medical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.051ef20ccbc94d37ab602098e3f67016
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/17588359211039930